Honghai xu

Honghai xu


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 February 2024 in Journal of Hepatology
Verified
Journal Article
Closed access
HDHanren Dai
Hanren Dai
CZCheng Zhu
Cheng Zhu
QHQian Huai
Qian Huai
WXWentao Xu
Wentao Xu
JZJiejie Zhu
Jiejie Zhu
Hua WangHua Wang
Hua Wang

9 September 2022 in Frontiers in Genetics
Verified
Journal Article
Open access
JQJiangfeng Qin
Jiangfeng Qin
WSWeijie Sun
Weijie Sun
HZHui Zhang
Hui Zhang
ZWZihao Wu
Zihao Wu
JSJiapei Shen
Jiapei Shen
HXHonghai xu
Honghai xu
Background: Previous studies have shown that Leukocyte cell-derived chemotaxin2 (LECT2) is associated with the development of HCC. However, there are still no studies with a comprehensive analysis of the role of LECT2 in hepatocellular carcinoma (HCC).Methods: TCGA data sets were used to analyze the expression of LECT2 in HCC. In addition, the prognostic value of LECT2 in HCC was also investigated. DriverDBv3 was used to analyze the Mutation, CNV, and methylation profiles of LECT2. And, validated by immunohistochemistry in 72 HCC samples. The prognostic value of LECT2 and the correlation with clinicopathological features were analyzed. The GO/KEGG enrichment analysis of LECT2 co-expression and gene set enrichment analysis (GSEA) was performed using the R software package. The PPI interaction network was constructed by Search Tool for the Retrieval of Interacting Genes (STRING) database. Immune infiltration was estimated by the XCELL, TIMER, QUANTISEQ, MCPCOUNTER, EPIC, CIBERSORT abs and CIBERSORT algorithms, and Spearman was used to analyzing their correlation with LECT2. Moreover, we analyzed the correlation of LECT2 expression with immune checkpoint molecules and HLA genes. Finally, we analyzed the IC50 values of six chemotherapeutic drugs by the pRRophetic package.Results: Reduced LECT2 expression levels found in HCC patients. Moreover, decreased levels of LECT2 were associated with poor overall survival, disease-free survival, disease-specific survival, and progression-free survival. Besides, methylation was significantly associated with LECT2 expression. The functional enrichment analysis revealed that LECT2 may affect HCC progression through various pathways such as JAK/STAT signaling pathway, cell cycle, and pathways in cancer. Additionally, the results showed that LECT2 expression was negatively correlated with immune infiltration of B cells, Neutrophil, Monocyte, Cancer-associated fibroblast, and Myeloid dendritic cell, and positively correlated with T cell CD8+ naive, Endothelial cell, and Hematopoietic stem cell. LECT2 expression was negatively correlated with multiple immune checkpoint molecules and HLA genes. Chemosensitivity analysis showed that chemosensitivity was lower in the LECT2 high expression group. We validated the prognostic value of LECT2 and analysis of clinicopathological features showed a lower TNM stage in the group with high expression of LECT2.Conclusion: Low expression of LECT2 in HCC is closely associated with poor prognosis, LECT2 may have potential clinical applications due to its unique immunological effects.

22 September 2021 in Frontiers in Molecular Biosciences
Verified
Journal Article
Open access
HXHonghai xu
Honghai xu
XLXutong Li
Xutong Li
ZWZihao Wu
Zihao Wu
LZLinyan Zhao
Linyan Zhao
JSJiapei Shen
Jiapei Shen
YGYufeng Gao
Yufeng Gao
Chronic hepatitis B (CHB) patients with severe liver fibrosis would be more likely to progress to a poorer prognosis. Treatment is considered once the liver fibrosis reaches significant liver fibrosis (≥S2). Leukocyte cell-derived chemotaxin-2 (LECT2) has been shown to contribute to liver fibrosis progression. No research has focused on the role of LECT2 in liver fibrosis in CHB patients. This study enrolled 227 CHB patients and divided them into the training group (n = 147) and validation group (n = 80), respectively. The expression of LECT2 in serum, protein and mRNA of the human liver tissues was detected to analyze the possible associations between LECT2 and liver fibrosis. A receiver operating characteristic curve (ROC) was used to estimate the efficacy of LECT2 for predicting liver fibrosis. The data showed that there was a positive relationship between LECT2 and the progression of liver fibrosis. In the training group, LECT2 was demonstrated to have better effectiveness than APRI and FIB-4. The AUC was 0.861, 0.698, and 0.734 for significant liver fibrosis, and 0.855, 0.769, and 0.752 for advanced liver fibrosis. Besides, the efficacy of LECT2 in different statuses of patients with CHB was examined and the effectiveness of LECT2 had also been confirmed in the validation group. All the results confirmed that LECT2 could act as a perfect predictor and thus offers a novel and direct biomarker to estimate liver fibrosis more accurately.

6 January 2026 in Gut
Verified
Journal Article
Closed access
LXLei Xiong
Lei Xiong
JHJianshang Huang
Jianshang Huang
YDYunsheng Dong
Yunsheng Dong
WHWei Han
Wei Han
WKWei-Ting Kuo
Wei-Ting Kuo
LZLi Zuo
Li Zuo
Objective: Immune checkpoint inhibitors (ICIs) have revolutionised cancer treatment and patients’ survival. However, ICIs also cause severe immune-related adverse events, notably colitis, resulting in ICIs therapy discontinuation and tumour immunotherapy failure. This study investigates long myosin light chain kinase 1 (MLCK1), a known regulator of tight junction and gut permeability, to elucidate the mechanisms underlying ICI-mediated colitis and identify approaches to reduce this toxicity. Design: This study employed an integrated approach, using clinical samples, in vivo models and in vitro organoid systems. Biopsies from patients with ICIs colitis were profiled using single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics. To recapitulate human ICIs colitis, we used a wild mouse microbiota (WildR) model, alongside various genetically modified and tumour-bearing models (including melanoma and MC38). Furthermore, mechanisms were investigated through organoid-immune cell co-cultures. Finally, surface plasmon resonance, microscale thermophoresis, full-spectrum flow cytometry, bulk RNA sequencing, immunostaining, ELISA and gut permeability assays were performed to comprehensively delineate the underlying molecular mechanism. Results: Tight junction integrity was compromised in both human ICIs colitis and our WildR mouse model. We determined that this barrier dysfunction is driven by activation of the MLCK1-mediated leak pathway following ICI treatment. Using murine models, we identified tumour necrosis factor secreted by CD8 + and CD4 + T cells as an upstream regulator that induces colitis through this MLCK-dependent mechanism, as genetic deletion of MLCK preserved the tight junction structure and ameliorated the inflammation and ICIs colitis. Furthermore, a pharmacological screen identified the small molecule Epicatechin, which blocks MLCK1-FKBP8 interaction and inhibits the recruitment of MLCK1 to the perijunctional actomyosin ring and prevents the intestinal barrier loss. Finally, treatment with Epicatechin mitigated ICI-induced colitis without compromising the antitumour efficacy of the immunotherapy. Conclusions: These findings suggest that MLCK1-dependent tight junction regulation is essential for ICIs colitis, positioning barrier restoration as a potential therapeutic strategy.

24 November 2025 in Hepatology Communications
Verified
Journal Article
Open access
HZHui Zhang
Hui Zhang
WWWei Wang
Wei Wang
YGYufeng Gao
Yufeng Gao
YQYuting Qian
Yuting Qian
WXWen Xu
Wen Xu
HXHonghai xu
Honghai xu
Background: Liver regeneration is a highly complex biological process, and the molecular mechanisms governing regenerative capacity exhibit significant divergence across distinct developmental stages. This study aimed to developmentally conserve pro-regenerative regulators of the liver and elucidate their mechanistic roles in the developmental stages of liver regeneration. Methods: Wild-type mice at distinct developmental stages, including 1-month-old (adolescent), 4-month-old (adult), 12-month-old (middle-aged), and 20-month-old (aged), underwent sham surgery or 2/3 partial hepatectomy. RNA sequencing and scRNA-seq identified the target gene and spatial expression. Hepatocyte proliferation was assessed by Ki-67, PCNA staining, and hematoxylin and eosin staining. Functional and mechanistic studies have employed bioinformatics, IF, coimmunoprecipitation, quantitative real-time PCR, and small-molecule inhibition. Results: RNA sequencing across age groups identified leukocyte cell–derived chemotaxin 2 (LECT2) as a functionally significant mediator in liver regeneration processes. Longitudinal assessment of murine liver regeneration models and patients who underwent hepatectomy revealed dynamic LECT2 expression patterns. LECT2 expression positively correlated with regeneration markers Ki-67 and PCNA. Lect2 -KO mice in 4 age groups exhibited impaired liver regeneration. Immunofluorescence staining and single-cell RNA sequencing demonstrated predominant hepatocyte-specific expression of LECT2. Hepatocyte-specific Lect2 knockout significantly impaired liver regeneration following 2/3 partial hepatectomy. Interestingly, there appeared to be no difference in the level of regeneration in mice with suppressed A Disintegrin and Metalloproteinase Domain 10 (ADAM10) expression despite Lect2 overexpression. Mechanistic investigations revealed that LECT2 potentiates hepatic regeneration by activating the ADAM10-NOTCH signaling pathway. Finally, our in vivo therapeutic model demonstrated that adeno-associated virus–mediated Lect2 overexpression significantly enhanced the posthepatectomy regenerative capacity. Conclusions: LECT2 promotes liver regeneration across developmental stages by activating the ADAM10-NOTCH signaling pathway, providing a promising therapeutic target for enhancing hepatic repair.

14 July 2026 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
WLWenyue Liu
Wenyue Liu
LLLi-you Lian
Li-you Lian
Seung Up KimSeung Up Kim
Seung Up Kim
Terry Cheuk-Fung YipTerry Cheuk-Fung Yip
Terry Cheuk-Fung Yip
SPSalvatore Petta
Salvatore Petta
MZMing-Hua Zheng
Ming-Hua Zheng
INTRODUCTION: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a prevalent chronic liver disease, and liver biopsy remains the gold standard for diagnosis. However, a subset of patients diagnosed with MASLD by imaging paradoxically exhibit steatosis grade S0 on liver biopsy, posing a diagnostic challenge. This study investigated the outcomes and causes of steatosis 0. METHODS: Steatosis 0 was defined as imaging-detected MASLD with a biopsy-defined steatosis grade S0. We used global cohorts to evaluate outcomes, histologic progression by paired biopsies, and possible causes. The cause analysis included MRI-proton density fat fraction (MRI-PDFF) for fat distribution, pathologist consistency testing, and comparison of serial biopsy sections. RESULTS: In a follow-up cohort of 3,273 biopsy individuals from 16 centers, 123 (3.8%) exhibited steatosis 0. Of these, 29.3% of them had advanced fibrosis (burnt-out MASLD) and demonstrated a risk of liver-related events, whereas those without advanced fibrosis had no such events. In the paired-biopsy cohort of 1,865 patients, 74 (4.0%) individuals initially showed steatosis grade S0; among them, 93.2% retained no or mild steatosis on follow-up biopsy. MRI-PDFF assessments in 42 MASLD patients revealed heterogeneous hepatic fat distribution, with some segments showing steatosis grade S0 despite elevated average liver fat. Interpathologist variability and discrepancies across consecutive biopsy sections contributed to misclassification of steatosis grade. DISCUSSION: Steatosis 0 represents a potential diagnostic gray zone in MASLD. It may be caused by burnt-out MASLD, uneven liver fat distribution, or variability in pathological assessment. Understanding the causes and implications of steatosis 0 is critical for diagnosis and management.